ILMN vs TMO: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

TMO is the larger of the two ($264.75B market cap): the incumbent the market prices for continued execution (25.72x forward earnings, beta 0.85). ILMN is the smaller challenger ($32.61B), actually pricier on forward earnings (34.88x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

ILMN vs TMO: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricILMNTMOWhat it tells you
Market cap$32.61B$264.75BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E34.8825.72Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E37.1237.69Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta1.450.85Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range52% of range97% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book10.424.83How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: TMO is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how ILMN and TMO affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ILMN and TMO share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ILMN and TMO exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Illumina (ILMN) do?

Illumina designs, makes, and sells next-generation DNA sequencing systems and the consumables that run on them, serving research, clinical, and applied-genomics customers. Its business follows a razor-and-blades model: instruments such as the high-throughput NovaSeq X, the NextSeq, and the benchtop MiSeq seed an installed base, and the bulk of revenue then comes from recurring sequencing consumables (reagents and flow cells), which historically make up the majority of sales. The company is also pushing into multiomics, proteomics, and clinical diagnostics to expand what its platforms can measure. Illumina is headquartered in San Diego, was founded in 1998, and is led by CEO Jacob Thaysen.

Full ILMN guide

What does Thermo Fisher Scientific (TMO) do?

Thermo Fisher Scientific, headquartered in Waltham, Massachusetts, is a global provider of scientific instruments, consumables, reagents, and services used across pharmaceutical and biotech drug development, clinical diagnostics, academic research, and environmental and industrial testing. The company operates through four reportable segments: Life Sciences Solutions (reagents, proteins, and consumables for research and bioproduction), Analytical Instruments (mass spectrometers, chromatography systems, electron microscopes, and laboratory equipment), Specialty Diagnostics (clinical diagnostic kits and transplant diagnostics), and Laboratory Products and Biopharma Services (supply-chain distribution, contract research through PPD, and contract drug manufacturing through Patheon). Revenue is generated through instrument sales, high-margin consumables and reagents that customers repurchase continuously, long-term service contracts, and growing contract development and manufacturing (CDMO) fees; consumables and services collectively account for a majority of annual sales and provide durable recurring revenue.

Full TMO guide

ILMN vs TMO: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • ILMN drivers: Installed base and the consumables annuity; The NovaSeq X transition.
  • TMO drivers: Bioprocessing and Biologic Drug Manufacturing Tailwind; Recurring Consumables and Reagents Engine.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Competition is intensifying: Ultima Genomics markets bulk whole-genome sequencing near $80 a genome, Element Biosciences' AVITI undercuts benchtop economics, and PacBio and Oxford Nanopore hold long-read niches, all pressuring Illumina's pricing and share. For TMO, the most significant near-term risk is a contraction in research funding from government agencies (including NIH) and from biotech companies whose access to capital markets has historically been cyclical; when funding tightens, customers delay instrument purchases and reduce consumable orders, pressuring organic revenue growth.

ILMN or TMO: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ILMN if you believe its drivers more; TMO if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ILMN and TMO guides.

ILMN vs TMO: the full fundamentals

ILMN. Illumina's multiple has expanded far faster than its earnings: the shares are up about 94% year to date and 172% over a year, while consensus calls for 2026 revenue growth near 11% and EPS of about $5.36. At roughly 43 times forward earnings and 36 times EV/EBITDA, the price assumes growth and margin expansion continue well beyond 2026, and the stock sits above the $241 average analyst target even as individual targets, such as JPMorgan's move to $320, have risen.

TMO. Thermo Fisher's multiple has expanded sharply since mid-2026 as organic growth re-accelerated: the stock trades at roughly 25 times forward earnings and ~37 times trailing GAAP earnings, which include heavy acquisition amortization. Analysts expect 2026 adjusted EPS of ~$25.14 on ~$47.9 billion of revenue, and ~$27.58 on ~$50.4 billion in 2027, both roughly 10% growth. The October 21 third-quarter report will test whether the second quarter's 5% organic growth holds; free cash flow of roughly $6.3 billion in 2025 still gives the company flexibility for repurchases, dividends and acquisitions.

Headline figures (approximate, October 2026): ILMN shows revenue (ttm) ~$4.49 billion; Q2 2026 revenue ~$1.16 billion, up ~9% year over year, 2026 revenue consensus ~$4.62 billion (~11% growth); 2027 consensus ~$4.92 billion, margins (ttm) Gross ~68%, operating ~21%, net ~18%, net income and eps (ttm) ~$824 million net income; EPS ~$5.39 trailing, ~$6.12 forward; TMO shows revenue (ttm) ~$46.3 billion; full year 2025 ~$44.6 billion, q2 2026 revenue ~$11.99 billion, up 10% reported and 5% organic, q2 2026 adjusted eps ~$6.03 (+13%) vs ~$5.71 expected, margins (ttm) Gross ~41%, GAAP operating ~19%, net ~15%.

The bottom line: ILMN vs TMO

ILMN and TMO are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ILMN and TMO exposure against your real portfolio. It is not an investment adviser.

Wondering how ILMN or TMO fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Illumina

Ask Walnut's AI anything about ILMN and see how it fits what you own.

FAQ

What is the difference between ILMN and TMO?

+

Illumina designs, makes, and sells next-generation DNA sequencing systems and the consumables that run on them, serving research, clinical, and applied-genomics customers. Thermo Fisher Scientific, headquartered in Waltham, Massachusetts, is a global provider of scientific instruments, consumables, reagents, and services used across pharmaceutical and biotech drug development, clinical diagnostics, academic research, and environmental and industrial testing. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is ILMN or TMO the better stock?

+

Neither is universally better. TMO is the larger incumbent; ILMN is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, ILMN or TMO?

+

On forward P/E (as of November 2026), ILMN trades at 34.88x and TMO at 25.72x, so TMO is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both ILMN and TMO?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of ILMN vs TMO?

+

ILMN: Competition is intensifying: Ultima Genomics markets bulk whole-genome sequencing near $80 a genome, Element Biosciences' AVITI undercuts benchtop economics, and PacBio and Oxford Nanopore hold long-read niches, all pressuring Illumina's pricing and share. The underlying sequencing market is growing slowly, and soft academic and research funding, including pressure on US research budgets, can delay instrument purchases. China is now only about 3% of revenue after Illumina was effectively shut out of that market, where domestic players BGI and MGI dominate. Tariffs and a relatively high valuation add further risk. Valuation is now a larger part of the risk: at about 48 times trailing earnings and roughly 8.8 times sales after a 94% gain in 2026, the stock trades above the average analyst target of about $241, and the consensus for the third quarter calls for EPS of about $1.36 on revenue of about $1.15 billion, roughly 1% growth. A recall listing for the NovaSeq 6000Dx server correction is a reminder that clinical instruments carry regulatory exposure. TMO: The most significant near-term risk is a contraction in research funding from government agencies (including NIH) and from biotech companies whose access to capital markets has historically been cyclical; when funding tightens, customers delay instrument purchases and reduce consumable orders, pressuring organic revenue growth. Thermo Fisher's active acquisition strategy carries integration and leverage risk, particularly after committing approximately $13 billion to mergers and acquisitions in 2025 alone; total debt stood near ~$42.6 billion against ~$4.1 billion of cash on the latest balance sheet, and a large deal that underperforms expectations could weigh on earnings and the balance sheet simultaneously. Geopolitical friction, particularly regarding China, creates both a demand risk (softer orders from Chinese academic and industrial customers) and a supply chain risk, while tariff policy changes can disrupt cost structures. Finally, valuation risk has grown: after a ~31% rally in three months the stock trades near ~37 times trailing GAAP earnings and ~25 times forward estimates, essentially at the ~$689 average analyst target, which leaves less room for disappointment if organic growth slips back from the second quarter's 5%.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ILMN or TMO; figures are approximate and dated (as of November 2026). Verify current data before investing.